

Index

a

- AA3H, 75, 211
- acid sphingomyelinase (ASMase), 30, 145, 241
- activated cell-permeable peptide dendrimer (ACPPD), 187
- agrobacterium-mediated gene transfer, 381
- α,α -disubstituted amino acids (dAAs), 30, 31, 79, 84–87, 212, 214, 384
- α -aminoisobutyric acid (Aib), 85
- α/β -peptides, 81, 82, 83
- α/γ -peptides, 83, 84
- α -helical peptides, 57–62, 123
- α -peptide, 80, 85
- AMAL therapeutics, 374
- 2-aminocyclohexylcarboxylic acid (ACHC), 212, 215
- 6-aminohexanoic acid (Ahx), 149, 268, 269, 375
- aminoisobutyric acid (Aib), 30
- amphipathic cationic peptides, 45
- amphipathic cell-penetrating peptides (CPPs), 20
- α -helical peptides, 57–62
- β -sheet peptides, 62–63
- M918, 64–65
- p14ARF, 64
- Pep-1, 64
- polyproline type II helical peptides, 63–64
- pVEC, 64
- amphipathic peptide (AMP), 57–65, 85, 150, 210, 224, 245, 246, 317
- amphipathic peptide-based method, 230–231
- amphiphilic α -helical antimicrobial peptide, 45
- amphiphilic CPPs, 382, 383, 384, 387, 388, 389
- anionic peptides, 20, 64, 393
- antimicrobial peptides (AMPs), 47, 84, 113, 150, 166, 187, 209
- antisense oligomers, 263, 265, 267
- antisense oligonucleotides (ASO), 237, 263, 375
- delivery system, for myotonic dystrophy, 34
- anti-TOMM20 antibody, 36
- APTstat3 cell-permeable peptide (APTstat3-9R), 190
- Arabidopsis thaliana*, 382, 384, 385, 387–389, 393
- Arg4-Arg5-dNal6 (D- β -naphthylalanine)-Arg7-Fpa8 (L-4-fluorophenylalanine), 129
- arginine-rich cell-penetrating peptides (CPPs), 20, 29, 206
- with α,α -disubstituted α -amino acids (dAAs), 30
- assembly system, 33–34
- bacterial cells, 149
- cell membrane penetration, 30
- cellular uptake mechanisms of, 141–151
- cytosolic delivery of functional molecules, 150
- endocytosis mechanisms of, 143–144
- enhanced cytosolic release systems, 36
- enhanced membrane penetration of, 148–149
- for extracellular vesicles and exosomes, 36–38
- gene interaction, 34
- genes and oligonucleotides delivery, 34–35
- ion-pairing and hydrogen bonding, 141, 142
- membrane penetration mechanisms of, 144–147
- molecular coating, 35–36
- multilamellar formation of membranes for, 148
- toxicity, 149–150
- with unnatural amino acids, 30–31
- arginine-rich peptides, 121, 123, 124, 125, 142, 143, 145, 146, 150
- arginine-rich R7W peptide, 125
- arginine-terminated nanoparticles with quantum dots, 36
- aromatic oligoamide foldamers, 88
- artificial cyclized helix-loop-helix (HLH) peptides, 32

- aR7W2 peptide, 144
 AVB-620, 23, 194, 376
 azurin, 62, 63
- b**
- BaC₁₅₋₂₄, 63
 benzylpenicillin, 209, 210
 β -amino acids, 80–83
 β/γ -peptides, 81, 82
 β -hairpin arginine peptides, 31
 β -peptide, 80–83
 β -peptide foldamers, 215
 β -sheet peptides, 62–63
 β -, γ - or δ -amino acids, 79
 bicyclic dodecaarginine (R12) preparation, 32
 biotinylated CPPs, 22
 blood-brain barrier (BBB), 37, 186, 209, 230, 294, 323, 357
 blood–cerebrospinal-fluid-barrier (BCSFB), 294
 bombinins, 117–120
 boron neutron capture therapy (BNCT), 151
 bovine serum albumin (BSA), 35, 249, 384
 BP100, 47, 48, 382, 383, 387, 392
 BP100(KH)₉, 47, 228
 (BP100)₂K₈, 47
 bPrPp, 60
- C**
- CADY, 61, 241
 CADY/siRNA complexes, 61
 cancer-targeting cell-penetrating peptides, 32–33
 CAP18 (106-121)-derived sC18 peptides, 38
 5-carboxyfluorescein (FAM), 144
 5- or 6-carboxyfluorescein (FAM), 206
 cargo molecules, 62, 69, 72, 143, 150, 205–207, 211, 212, 347, 386, 388, 392
 18 kDa cationic antimicrobial peptide cathelicidin (CAP18), 47
 cationic CPP oligoarginines, 22
 cationic CPPs, 17, 19–22, 45, 47, 64, 75, 85, 86, 161, 163, 231, 239, 241, 267, 277, 317, 322, 324, 333, 348, 356, 384, 386, 388, 389
 cationic peptide-based method, 229–230
 caveolae, 160
 caveolin-mediated endocytosis, 111, 240, 246
 Cecropin A, 116
 cell drinking process, 160
 cell-penetrating peptides (CPPs), 1, 57, 219, 315, 315–316, 331, 367, 381
 applications, 323–324, 349
 artificial, 383–385
 cellular internalization, 317, 319–320
 characteristics of, 239
 chemical structures, 21–22
 classification, 18
 clinical trial, 367–376
 conjugated polymer micelles, 285–286
 conjugates for nucleic acid delivery, 242–243
 CPP-PMO, 243
 CPP-PNA, 242–243
 design and availability, 382–383
 direct translocation, 241
 electrophysiological analysis of the direct penetration of, 113–128
 endocytosis-dependent mechanism, 239, 241
 experimental readout, 344–345
 functionalization, 247–250
 histidine-rich CPPs, 48–51
 homing peptide sequences, 250
 improvement, 324
 internalization mechanism, 239–241, 386–389
 intestinal barrier, 347
 mucus, 347
 transepithelial transport, 347–349
 intestinal injection, 344
 intracellular delivery of drugs, 207
 in vivo distribution of, 184
 in vivo methods, 343
 oral gavage, 343–344
 lipid-grafting, 248–249
 lists of, 2
 for liver targeting, 323
 lysine-rich CPPs, 45–48
 modified lipid nanoparticles, 321–324
 molecular dynamics (MD) simulation, 129–131
 molecular imaging, 183
 nanoparticles for nucleic acid delivery, 243–247
 oral administration safety, 345–346
 oral delivery of biopharmaceuticals, 331
 carriers, 333–342
 challenges, 331–333
 formulation, 342
 transepithelial cargo absorption, 333, 341
 origins, 22–23
 PEGylation, 249
 pharmacokinetics of, 184–185
 physical and chemical properties and structures of, 111
 physicochemical properties, 17, 19–21
 polymer micelles, 287
 polypeptide-based carriers, 389–393
 region-dependent CPP-mediated intestinal absorption, 342
 reporting and statistical analysis, 346
 in situ administration, 344

- solid-state NMR analysis of the direct penetration of, 128–129
for tumor targeting, 322–323
types, 317
typical classifications, 111, 112
- cellular internalization, 124, 223, 240, 241, 245, 315, 316, 317, 319–322
- C-end Rule (CendR), 32, 33
- central nervous system (CNS), 209, 294
- charge flux, 117–120
- chimeric CPPs, 22, 23
- chimeric peptides, 72, 243, 317, 383
- ciprofloxacin, 212, 214
- c-Jun N-terminal kinase inhibitor 1 (D-JNK-1), 371, 372
- clathrin and caveolin-independent endocytosis, 111
- clathrin-coated vesicles, 160
- clathrin-mediated endocytosis, 111, 144, 160, 161, 162, 319, 321, 387
- Clavanin A, 115
- conjugating CPPs, 183
- covalent conjugation, of oligoarginine, 38
- covalent methods, 223
chemical method, 224, 227
genetic method, 224
- CPP-conjugates
for cancer treatment, 190–196
for CNS disorders, 186–187
for infectious diseases, 187–189
- CPP-PMO, 243
- CPP-PNA, 242–243
- C-terminal structures, 17, 22
- C105Y, 73, 317
- cyclic arginine-rich peptides, 31–32, 243
- cyclic-R9 peptide-decorated nanoparticles, for oral delivery, 31
- Cyclorasin 9A5, 129
- cyclosporin A (CsA), 208, 209
- cysteine perfluoroarylation reaction, 32
- cystic fibrosis, 277
- cystic fibrosis transmembrane conductance regulator (CFTR), 277
- Cyt c⁷⁷⁻¹⁰¹, 47
- Cytosolic Tat, 164
- d**
- deep learning approach, 269
- deferoxamine, 209
- dendrimer structures, of arginine-rich peptide, 35
- D-formed octaarginine (r8), with stearyl moiety, 37
- 1,2-dimyristoyl-*sn*-glycero-3-phosphocholine (DMPC), 128
- 1,2-dimyristoyl-*sn*-glycero-3-phospho-(1'-*rac*-glycerol) (sodium salt) (DMPG), 129
- dioleoyl phosphatidylcholine (DOPC), 130, 131, 146
- dioleoyl phosphatidylcholine (DOPC) bilayer membrane, 124
- dioleoyl phosphoethanolamine (DOPE), 321–322
- 1, 2-dioleoyl-*sn*-glycero-3-phosphoethanolamine (DOPE), 128
- 1,2-dioleoyl-*sn*-glycero-3-phospho-*rac*-(1-glycerol) sodium salt, 62
- direct plasma membrane translocation, 159, 171
- direct translocation, 239, 241, 245, 269, 348
- dodeca (R12)-arginine-conjugated exosomes, 38
- D-oligoarginines, 21
- doxorubicin (Dox), 33, 206, 207, 208, 210, 211, 323, 374
- dppz-Xentry peptide, 34
- droplet contact method, 113, 114
- droplet interface bilayer, 113
- drug delivery
amphipathic peptides, 210
Arg-rich peptides, 206–209
cationic peptides, 209, 210
foldamers, 212–215
hydrophobic peptides, 211–212
water solubility of, 205
- drug delivery system (DDS) tools, 20, 23
- D-Tat, 21
- Duchenne muscular dystrophy (DMD), 237, 243, 264, 275–276, 278
- e**
- electroporation, 149, 224, 265, 266
- endocytic pathway, 160–162, 166–172, 174, 175, 227, 270, 294, 319
- endocytic uptake, 126, 144, 159, 162, 171, 173, 174, 273, 348
- endocytic vesicles, 160, 166, 167
- endocytosis, 319
CPPs, 161–162
endocytic pathway, 160–161
types of, 160
- endocytosis-dependent internalization, 240, 241, 246, 319
- endocytosis-dependent mechanism, 239, 241, 246
- endocytosis-independent entry, 317, 319
- endocytosis mechanisms, of arginine-rich cell-penetrating peptides, 143

- endosomal escape
 direct modification of, 173
 disadvantage, 174–175
 endocytic pathway, 170–171
 endocytosis, 160–162
 evidence
 non-toxic, 169
 toxic, 168–169
 mechanisms of, 163
 leaky fusion, 162–165
 membrane destabilization/
 permeabilization, 165–166
 proton sponge effect, 166–167
 membrane leakage, 171–172
 small molecules, 173–174
 toxic or not, 170
- Endosomal Sorting Complexes Required for
 Transport (ESCRT) complex, 170, 174
- EpN18 peptide, 148, 149
- EPR effect, 287, 292, 297, 301, 302, 322
- f**
- fallypride, 209
- fluorescein isothiocyanate (FITC), 73, 186, 211
- fluorescence microscopy, 162, 168, 171,
 172, 267
- fluorescent dye, 23, 196, 367, 376
- fluorophore-conjugated CPPs, 23
- fluorophores, 23, 173
- foldamers
 α,α -disubstituted amino acids (dAAs), 84–86
 aromatic oligoamide foldamers, 88
 β -amino acids, 80–83
 γ -amino acids, 83–84
 oligoureas, 87
 poly-N-substituted glycine oligomers, 86
- F4R4 peptides, 34
- fusogenic peptides, 165, 241, 246, 322, 324
- g**
- GALA peptide, 20, 61, 246, 322–324
- γ -amino acids, 83–84
- γ -peptide, 83, 84
- Gaussian accelerated molecular dynamics
 (GaMD) simulation, 385
- Generally Regarded as Safe (GRAS), 249
- genetic disease, 251, 264, 270, 275–277
- genetic method, 222, 224
- giant plasma membrane vesicles (GPMVs), 145
- glutathione (GSH), 207, 227, 285, 288, 294, 297
- glycosaminoglycans (GAGs), 60, 63, 125, 126,
 142, 146, 239
- gold nanoparticles (AuNPs), 35
 BSA-r8 coating, 36
- GST-Grb2 SH2-MTS1 fusion protein,
 72
- h**
- hCT(9-32)-br, 73
- hCT(18-32)-br, 74
- hexaarginine-conjugated Van derivatives, 188
- 1,1,1,3,3,3-hexafluore-2-propanol, 58
- Hibiscus cannabinus*, 385
- histidine-rich CPPs, 45, 48–51, 49
- HIV-1 Nef DNA delivery, 35
- HIV Tat peptide, 266, 267
- HL6 peptide, 50
- homing peptide sequences, 250
- host-directed PPMOs, 273
- Hutchinson-Gilford progeria syndrome
 (HGPS), 276–277
- hyaluronic acid (HA), 193
- hydrazone, 207
- hydrophobic CPPs, 20
 AA3H, 75
 C105Y, 73
 examples of, 70
 hCT(9-32)-br, 73
 hCT(18-32)-br, 74
 hydrophobic MPS, 72
 L1-7, 75
 M918, 74
 membrane-translocating sequence, 72
 MPG, 69
 MTS1, 72
 P4, 74–75
 Pep-7, 73
 Pept1, 74
 PFV, 74
 substance P analog, 72
 TP10, 72–73
 translocation motif (TLM), 73
- hydrophobic MPS, 72
- i**
- inflamed tissue, 287, 301–304, 307
- instantaneous membrane defect, 115
- intracellular delivery systems, 29, 39
- intranasal administration, 355
 bioavailability, 355
- ion channel/pore-forming peptides, 113
- k**
- KAI Pharmaceuticals, 371
- KALA, 62, 246
- K16ApoE, 186, 187
- K-homology splicing regulatory protein
 (KHSRP), 273
- l**
- LAH4, 51, 61
- L17E, 61

leaky fusion, 162–165
 leucine (L)–lysine (K) sequence, 120
 levofloxacin, 212, 214
 LH peptide, 50
 linear CPPs, 21
 lipid-grafting, 248–249
 lipid nanoparticles (LNPs), 315–316, 321–324
 types, 320–321
 lipopeptides, 34, 249
 liraglutide (LRT), 32
 L8K6, 120–122
 L12K9, 120, 121
 L16K12, 120–122
 LK peptides, 120, 122, 123
 LL-37, 116
 low-molecular-weight (LMW) drugs,
 367, 374–375
 L-peptide bombinin H2, 117
 LTP peptides, 35
 lysine-rich CPPs, 38, 45–48, 382, 389
 lysophosphatidylcholine (LPC), 164
 lysosomal-associated membrane protein 1
 (LAMP1), 161

m

M918, 35, 64–65, 74
 machine learning, 268, 269
 macropinocytosis, 29, 36, 37, 38, 60, 61, 65, 74,
 141, 142, 143, 160–162, 169, 228, 240,
 241, 285, 286, 292, 319, 321, 386, 387
 macropinocytosis-inducible exosomal
 system, 37
 macropinocytosis pathway, 29, 292, 386
 macropinosomes, 161, 162
 Magainin 1, 114, 116
 melittin, 20, 128, 348, 349
 membrane destabilization/
 permeabilization, 165–166
 membrane penetration mechanisms, of
 arginine-rich peptides, 144–147
 membrane repair, 165, 170, 171, 241
 membrane-translocating sequence, 72
 messenger RNAs (mRNAs), 23, 237, 238, 264,
 271, 276, 375
 methicillin-resistant *Staphylococcus aureus*
 (MRSA), 188, 212
 miniprotein structures, 269
 Mitoparan (INLKKLAKL(Aib)KKIL), 47
 M-lycotoxin, 61
 model amphipathic peptide (MAP), 20, 22, 45,
 47, 58, 60, 85, 184, 317
 molecular dynamics (MD) simulation, 112,
 129–131, 146, 149, 164, 387
 monomers, 79, 80, 114, 386
 Montal-Mueller/painting methods,
 113

MPG, 22, 35, 62, 69
 MTS1, 72
 multilamellar formation of membranes for
 membrane penetration of arginine-rich
 peptides, 148
 multiple/stable pBLMs, 113
 muscle-specific peptide (MSP), 243

n

nanocarriers with R9 peptides, 33
 nano DDS, 21, 23
 NickFect70, 51
 non-arginine-containing P9W, 124
 non-cationic cell-penetrating peptide
 (AA3H), 211
 noncovalent conjugation method, 222
 noncovalent method, 223, 224, 228–229
 non-proteinogenic amino acids, 22, 79–80,
 85, 86, 89
 nose-to-brain drug delivery, 294–297, 357–358
 by coadministration with CPPs, 357–358
 mechanistic insight, 358–360
 therapeutic effects, 360–362
 NRP-1-targeted peptide, 33
 nuclear localization sequences (NLS), 35, 50,
 72, 242, 248, 250
 nucleic acid delivery, 243–244
 PepFect family, 245
 RALA family, 246–247
 WARP family, 245–246
 nucleic acids (NAs), 21–23, 45, 51, 57, 58, 62,
 69, 79, 161, 165, 167, 183, 237, 265, 285,
 286, 295–297, 304, 315, 320, 321, 362,
 367, 375–376

o

octa (R8)-arginine-conjugated exosomes, 38
 octa-arginine peptide, 45
 octa-D-arginine (r8), 208
 oligoamide foldamers, 88, 89
 oligoarginines, 19, 21, 22, 29, 38, 85, 86, 141,
 144, 145, 150, 206, 209, 212, 228, 231,
 268, 285, 286, 292, 316, 317, 333, 386
 with exosomal membrane proteins, 38
 oligonucleotides (ONs), 34–35, 62, 69, 173,
 237–238, 268, 269, 273, 297
 oligoprolines, 83, 124
 oligourea foldamer, 87–89
 oligoureas, 87
 oral delivery, 1, 31, 304–307, 331–350

p

P4, 74–75
 Pardaxin P5, 116
 p14ARF, 35, 64, 74

- parylene double-well (PDW) chip, 113
 pDNA delivery, 88, 245, 249, 288–292
 PEGylation, 248–249, 287, 288, 301
 Penetratin, 17, 22, 45, 57, 184, 241, 242
 Pep-1, 64
 Pep-7, 73, 317
 PepFect 3 (PF3), 245
 PepFect family, 240, 245
 Pept1, 74
 peptide-based nanoparticles (PBNs), 238
 peptide development, 241, 267–270
 peptide lengths, range of, 21
 peptide-modified exosomes, cellular uptake of, 38
 peptide nucleic acids (PNAs), 23, 60, 74, 231, 242
 peptide-PMO (PPMO)
 bacteria and protists, 273–275
 genetic disease, 275–277
 peptide development, 267–270
 platform technology, 270–278
 viruses, 270–273
 peptide receptor radionuclide therapy (PRRT), 250
 peptoids, 86
 PFV, 74
 pharmacokinetics
 of CPP-conjugates for cancer treatment, 190–196
 of CPP-conjugates for CNS disorders, 186–187
 of CPP-conjugates for infectious diseases, 187–189
 of CPP-conjugates for inflammatory diseases, 189–190
 of CPPs, 184, 185
 pH-low insertion peptides (pHLIP), 242
 phosphorodiamidate morpholino oligomers (PMOs), 263, 375
 phosphorodiamidate morpholino oligonucleotides (PMOs), 32, 243
 phosphorylated epidermal growth factor receptor (EGFR), 72
 PICsome, 393
 planar bilayer lipid membrane (pBLM), 113–114
 plasmid DNAs (pDNAs), 22, 23, 31, 60, 85, 237, 285, 319, 375, 386
 poly(ethylene glycol) (PEG), 33, 188, 287, 320
 polyelectrolyte complex (PEC), 292
 polyethylene glycol-phosphatidylethanolamine (PEG-PE), 164
 polyhistidine peptides (PHPs), 50, 383
 poly ion complex micelles (PICs), 287
 polylysine, 47, 242, 246
 polymer micelles, 287
 multifunctional peptide-conjugated, 297
 poly-N-substituted glycine oligomers, 86
 poly-proline-arginine (poly-PR), 149
 polyproline-containing arginine-rich peptide P9R7W, 124
 polyproline II (PPII) helix, 123–125, 128
 polyproline II (PPII) helix structure, 123, 126
 polyproline type II helical peptides, 63
 poly(chloro-*p*-xylylene) (parylene) separator, 113
 pore-forming peptides, 113, 114, 128, 166
 positive charge-independent histidine-rich CPPs, 50
 ppTG1, 60
 ppTG20, 60
 Pro-Arg-rich antimicrobials, 63
 progerin, 276, 277
 proline-based γ -amino acids, 83
 proline-rich peptides, 123, 124
 protein-derived CPPs, 21–22
 protein kinase C- α (PKC α), 143
 proteinogenic amino acids, 21
 protein pharmaceuticals, 373
 protein-protein interactions (PPIs), 32, 190, 223
 protein transduction domains (PTDs), 1, 316
 proton sponge effect, 50, 51, 162, 163, 166–167, 241, 286, 297, 299
 PsorBan, 367, 371
 pVEC, 64, 130, 184, 210
- r**
- Rab7, 144, 161, 164
 RALA family, 246–247
 RA therapy, 301
 r7-conjugated CsA, 208, 209
 REDV-TAT-NLS-H12, 50, 51
 R₁LS (1st generation dendritic arginine), 34
 R₂LS (2nd generation dendritic arginine), 34
 gene transfection efficacy, 34
 R₃LS (3rd generation dendritic arginine), 34
 R16-modified exosomes, with saporin encapsulation, 38
 RNA interference (RNAi), 238, 286
 ruthenium (II) dipyridophenazine (dppz), 34
 R₆W₃, 60
- S**
- Sarepta Therapeutics, 237, 375
 sC18, 38, 47
 siRNA delivery, 88, 246, 285–307
 SL-37, 116
 small interfering RNAs (siRNAs), 23, 61, 74, 85, 190, 237, 238, 248, 249, 285, 292, 304, 323, 375, 392

- SNIPER, 230
Solanum lycopersicum, 383
solid phase peptide synthesis (SPPS), 248
solid-state NMR analysis, of direct penetration
of CPPs, 128–129
spinal muscular atrophy (SMA), 238, 276
stable nucleic acid lipid particles
(SNALPs), 321
stearylated CPPs, 22
stearyl-r8-Exo induced macropinocytosis, 37
structure-activity relationship (SAR), 47, 173,
243, 246, 268
substance P analog, 72
surfactant-like peptides (SLPs), self-
assembly of, 33
survival motor neuron 1 protein (SMN1), 238
sweet arrow peptide (SAP), 63
SynB-conjugated doxorubicin, 210
synthetic CPP, 22, 73
- t**
Tat-conjugated polymer micelles, 288
tetramethylrhodamine (TMR), 164
TH peptide, 48
TK peptide, 47, 48
TP10-conjugated vancomycin, 212, 213
transacting activator of transcription (TAT)
peptide, 219, 316
transactivator of transcription (Tat) protein, 1,
19, 22, 219, 285
translocation motif (TLM), 73
transmembrane peptide structures, 114
transportan, 17
transportan, 20, 60, 72, 73, 195, 242, 317,
383, 389
transportan 10 (TP10), 60, 72–73, 184, 188, 211,
212, 245
Trojan peptides, 1, 316
tumor-homing CPPs, 33
tumor-homing peptides, 194, 196
tumor-penetrating peptides (TPPs), 32, 33
tumor tissue, 48, 184, 190, 193–196, 289, 291,
292, 297–301
- v**
vancomycin (Van), 187–189, 212
vascular endothelial growth
factor (VEGF), 292
VT5, 20, 62
- w**
WRAP family, 245–246
- Z**
Zolgensma (Novartis), 238

